Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine

Cytotherapy

Volumn 6, Issue 4, 2004, Pages 344-355

  Peled, T ^a   Mandel, J ^a   Goudsmid, R N ^a   Landor, C ^a   Hasson, N ^a   Harati, D ^a   Austin, M ^a   Hasson, A ^a   Fibach, E ^b   Shpall, E J ^c   Nagler, Arnon ^d  

^a Gamida Cell Ltd Cell Therapy Technologies   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Hematology Division ^*

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Ex vivo large scale expansion; Pre clinical development; Tetraethylenepentamine

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CHELATING AGENT; COPPER; CYTOKINE; FLT3 LIGAND; INTERLEUKIN 6; POLYAMINE DERIVATIVE; STEM CELL FACTOR; TETRAETHYLENEPENTAMINE; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL RENEWAL; CLINICAL TRIAL; COLONY FORMING CELL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EX VIVO STUDY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MALIGNANT NEOPLASTIC DISEASE; MODULATION; MOUSE; NEWBORN; NONHUMAN; PURIFICATION; SEPARATION TECHNIQUE; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

EID: 4544362434     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410004916     Document Type: Article

References (27)

1. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66.
2. Ballen K, Broxmeyer HE, McCullough J et al. Current status of cord blood banking and transplantation in the United States and Europe. Biol Blood Marrow Transplant 2001;7:635-45.
3. Risdon G, Gaddy J, Broxmeyer HE. Allogeneic responses of human umbilical cord blood. Blood Cells 1994;20:566-70.
4. Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002;14:160-4.
5. Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815-22.
6. Broxmeyer HE, Hangoc G, Cooper S et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA 1992;89:4109-13.
7. McNiece I, Jones R, Cagnoni P et al. Ex vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther 1999;41:82-6.
8. Koller MR, Manchel I, Maher RJ et al. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplant 1998;21:653-63.
9. McNiece I, Kudegov D, Kerzic P et al. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp Hematol 2000;28:1181-6.
10. Bruno S, Gammaitoni L, Gunetti M et al. Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. J Biol Regul Homeost Agents 2001;15:38-48.
11. Piacibello W, Gammaitoni L, Bruno S et al. Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. J Hematother Stem Cell Res 2000;9:945-56.
12. Henon P, Sovalat H, Becker M et al. Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol 1998;103:568-81.
13. +. J Biol Regul Homeost Agents 2001;15:62-7.
14. -. Leukemia 2003;17:960-4.
15. + cells. Br J Hematol 2002;116:655-61.
16. Peled T, Landau E, Mandel J et al. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord-blood-derived CD34(+) cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol 2004;32:547-55.
17. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92:10119-22.
18. Lewis ID. Clinical and experimental use of umbilical cord blood. Intern Med J 2002;32:601-9.
19. Astori G, Malangone W, Adami V et al. A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use. Blood Cells Mol Dis 2001;27:715-24, 725-7.
20. Shpall EJ, Quinones R, Giller R et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002;8:368-76.
21. Jaroscak J, Goltry K, Smith A et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003;101:5061-7.
22. + cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection device. J Hematother 1998;7:457-61.
23. + cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 1998;16:387-96.
24. Yin AH, Miraglia S, Zanjani ED et al. CD133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
25. + cells from human umbilical cord blood. Br J Haematol 2000;108:793-800.
26. + selection: from laboratory experience to the first transplantation of a pediatric patient with relapsed leukemia. Blood 2001;98:851a.
27. + cord blood cells. Transfusion 2003;43: 383-9.